9989 — Shenzhen Hepalink Pharmaceutical Co Share Price
Last trade - 00:00- HK$6.47bn
- HK$10.16bn
- CNY7.16bn
- 32
- 71
- 37
- 43
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 5.42 | ||
| PEG Ratio (f) | 0.23 | ||
| EPS Growth (f) | 31.45% | ||
| Dividend Yield (f) | 2.76% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.47 | ||
| Price to Tang. Book | 0.62 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.9 | ||
| EV to EBITDA | 10.97 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4% | ||
| Return on Equity | 4.65% | ||
| Operating Margin | 9.45% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 4,814.97 | 4,624.65 | 5,332.07 | 6,365.18 | 7,159.41 | 7,851.36 | 8,762.96 | 20.28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +225.82 | +64.79 | -17.66 | -61.93 | +82.4 | +38.26 | +24.63 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The Company distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.
Directors
- Li Li CHM (57)
- Bin Zhang CFO (44)
- Yu Shan GMG (61)
- Tan Li DGM (57)
- Sze Ting Chan SEC
- Fengqi Qian SEC (36)
- Junfa Chen IND (56)
- Chuan Lu IND (51)
- Zhaohui Wang IND (43)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- April 21st, 1998
- Public Since
- May 6th, 2010
- No. of Shareholders
- 29,818
- No. of Employees
- 2,366
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,467,296,204
- Address
- No. 19, SHENZHEN, 518057
- Web
- https://www.hepalink.com/
- Phone
- +86 75526980311
- Auditors
- Ernst & Young Hua Ming
Upcoming Events for 9989
Similar to 9989
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 07:10 UTC, shares in Shenzhen Hepalink Pharmaceutical Co are trading at HK$4.41. This share price information is delayed by 15 minutes.
Shares in Shenzhen Hepalink Pharmaceutical Co last closed at HK$4.41 and the price had moved by -29.67% over the past 365 days. In terms of relative price strength the Shenzhen Hepalink Pharmaceutical Co share price has underperformed the FTSE Developed Asia Pacific Index by -21.34% over the past year.
The overall consensus recommendation for Shenzhen Hepalink Pharmaceutical Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Shenzhen Hepalink Pharmaceutical Co dividend yield is 2.5% based on the trailing twelve month period.
Last year, Shenzhen Hepalink Pharmaceutical Co paid a total dividend of CNY0.10, and it currently has a trailing dividend yield of 2.5%.Looking ahead, the next dividend pay date is 2023-08-15.
We do not have data on when Shenzhen Hepalink Pharmaceutical Co is to next pay dividends. The historic dividend yield on Shenzhen Hepalink Pharmaceutical Co shares is currently 2.5%.
To buy shares in Shenzhen Hepalink Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$4.41, shares in Shenzhen Hepalink Pharmaceutical Co had a market capitalisation of HK$6.47bn.
Here are the trading details for Shenzhen Hepalink Pharmaceutical Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 9989
Based on an overall assessment of its quality, value and momentum Shenzhen Hepalink Pharmaceutical Co is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Shenzhen Hepalink Pharmaceutical Co is HK$8.27. That is 87.51% above the last closing price of HK$4.41.
Analysts covering Shenzhen Hepalink Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of CNY0.67 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shenzhen Hepalink Pharmaceutical Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -15.19%.
As of the last closing price of HK$4.41, shares in Shenzhen Hepalink Pharmaceutical Co were trading -19.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shenzhen Hepalink Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 5.42. The shares last closed at HK$4.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Shenzhen Hepalink Pharmaceutical Co's management team is headed by:
- Li Li - CHM
- Bin Zhang - CFO
- Yu Shan - GMG
- Tan Li - DGM
- Sze Ting Chan - SEC
- Fengqi Qian - SEC
- Junfa Chen - IND
- Chuan Lu - IND
- Zhaohui Wang - IND